Article citationsMore>>

Gudjonsson, J.E. and Elder, J.T. (2012) Psoriasis. In: Wolff, K., Goldsmith, L.A., Katz, S.I., Gilchrest, B.A., Paller, A.S. and Leffell, D.J., Eds., Fitzpatrick’s Dermatology in General Medicine, 8th Edition, The McGraw-Hill Companies, Singapore, 197-231.
https://doi.org/10.1111/j.1524-4725.2008.34211.x

has been cited by the following article:

• TITLE: A New Regimen in the Treatment of Psoriasis Using Oral Methotrexate

  AUTHORS: Khalifa E. Sharquie, Adil A. Noaimi, Mays H. Alobaidi

  KEYWORDS: Psoriasis, Methotrexate, New Regimen

  JOURNAL NAME: Journal of Cosmetics, Dermatological Sciences and Applications, Vol.9 No.2, June 5, 2019

  ABSTRACT: Background: Methotrexate is a well-known standard therapy for psoriasis. The standard regimen is using six (2.5 mg) tablets/week that might be with many side effects. Objective: Finding a new regimen for oral methotrexate aiming to decrease side effects and increase its effectiveness. Patients and Methods: This therapeutic, comparative study done at the Center of Dermatology, Medical city, from October 2017 to October 2018. Fifty-three patients with moderate to severe psoriasis completed the study. They were divided into: Group (A) (27) patients were treated with the new oral regimen and Group (B) (26) patients were treated with the six tablets/week. Investigations including CBC, LFT and RFT were done. PASI score, BSA and side effects especially gastrointestinal ones were recorded. Results: They were 29 males and 24 females. Age ranged from 18 - 67 years. Disease duration ranged from 1 - 30 years. BSA involved ranged from 20% - 79%. The PASI score ranged from 10.2 - 45.7. After 8 weeks of treatment, there was statistically significant difference (p-value > 0.001) regarding PASI score and gastrointestinal side effects being less in Group (A). Group A patients were more satisfied. Conclusion: The new regimen used in the present study has lower gastrointestinal side effects and more efficacy.